Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RET/PTC Rearrangement

Known as: RET Gene Rearrangement 
A gene rearrangement involving the RET proto-oncogene. RET gene rearrangements are associated with several different neoplastic conditions.
National Institutes of Health

Related topics

Related topics

15 relations
Columnar Cell Variant Thyroid Gland Papillary CarcinomaCribriform-Morular Variant Thyroid Gland Papillary CarcinomaEncapsulated Follicular Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary Carcinoma
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
BACKGROUND RET/PTC rearrangement, RAS, and BRAF mutations are considered to be mutually exclusive in papillary thyroid carcinoma… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Highly Cited
2009
Highly Cited
2009
High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma
Purpose: Papillary thyroid carcinoma (PTC), the most common thyroid malignancy, usually possesses BRAF mutation or rearranged in… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
2008
2008
Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement
Purpose: Papillary thyroid carcinomas (PTC) are the most common type of thyroid malignancy with one of the two mutations, RET/PTC… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
Highly Cited
2007
Highly Cited
2007
Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
OBJECTIVE To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in order to assess FNAB… Expand
  • table 1
  • figure 1
Highly Cited
2005
Highly Cited
2005
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis
Thyroid cancer poses a significant clinical challenge, and our understanding of its pathogenesis is incomplete. To gain insight… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 4
Highly Cited
2004
Highly Cited
2004
Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis
Follicular epithelial cell-derived thyroid tumors are common neoplasms comprised mainly of benign thyroid adenomas, follicular… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2003
Highly Cited
2003
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Rearrangement of RET proto-oncogene is the major event in the etiopathogenesis of papillary thyroid carcinoma (PTC). We report a… Expand
  • table 1
  • figure 1
Review
2002
Review
2002
RET/PTC rearrangement in thyroid tumors
Rearrangement of the RET gene, also known as RET/PTC rearrangement, is the most common genetic alteration identified to date in… Expand
  • figure 1
Highly Cited
2002
Highly Cited
2002
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma.
The tall-cell variant (TCV) of papillary thyroid carcinoma (PTC), characterized by tall cells bearing an oxyphilic cytoplasm, is… Expand
Highly Cited
2001
Highly Cited
2001
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.
Rearrangements of the RET proto-oncogene may occur in both naturally occurring and radiation-induced papillary thyroid carcinomas… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE